Jcr Pharmaceuticals Co., Ltd. · TSE:4552

Jcr Pharmaceuticals — H1 FY2020 Earnings Presentation

15 slides from Jcr Pharmaceuticals's earnings presentation, Nov 2, 2020

  1. Slide 1: FY2020 First-Half results Briefing Session

    FY2020 First-Half results Briefing Session Financial Results –Six Months Ended Sep.30, 2020 (2Q FY2020)－ November 2, 2020 JCR Pharmaceuticals co., Ltd. 【Securities code】4552, 1st Sec. TSE Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.

  2. Slide 2: Financial highlights (2Q FY2020 results)

    Financial highlights (2QFY2020 results) Net sales and Profits fell short of the 2Q forecast Unit: million yen Initial Forecast Results Difference (2020/5/12) Net Sales 14,400 10,951 (3,449) (24.0)％ Operating Income 3,600 1,307 (2,293) (63.7)％ Ordinary Income 3,600 1,351 (2,249) (62.5)％ 2Q FY2020 res

  3. Slide 3: Consolidated Results

    Consolidated Results Six Months Ended FY2020 (Unit: Million yen) Sep. 30, 2020 (Apr. 1, 2020- Mar. 31, 2021) Six Months Ended Consolidated Expected Sep. 30, 2019 Initial Forecast A Year-on-Year progress rate B A/B Net Sales 11,236 10,951 (2.5)% 27,200 40.3% Cost of Sales 3,173 3,513 10.7% 6,800 51.7

  4. Slide 4: Sales by business Segments

    Sales by business Segments (Consolidated) (Unit: Million yen) FY2020 Six Months Ended Six Months Ended (Apr. 1, 2020- Sep. 30, 2019 Sep. 30 2020 Mar. 31, 2021) Expected Composition Composition Year-on- Forecast progress A ratio ratio Year B rate A/B GROWJECT® 6,235 55.5% 6,538 59.7% 4.9% 13,270 49.3

  5. Slide 5: Trend in Sales by business Segments

    Trend in Sales by business Segments (Consolidated) (Unit: Million yen) 1,051 773 1,048 74 194 7 10 2,506 1,002 220 219 1,599 784 274 123 1,027 1,054 74 512 1,527 1,412 Other 1,625 1,694 1,182 1,052 License Revenue 989 545 558 586 958 Agalsidase Beta BS 725 427 TEMCELL 2,345 2,272 1,825 261 2,098 1,6

  6. Slide 6: Year-on-year changes (Consolidated)

    Year-on-year changes (Consolidated) ◆ Net Sales 10,951 million yen, Year-on-year (285) million yen (Unit: Million yen) Six Monts Ended Sep. 30, 2019 11,236 Main increase/decrease GROWJECT ＋303 ・ GROWJECT: market penetration of Epoetin Alpha BS (576) reformulated products +303 million yen Darbepoetin

  7. Slide 7: Balance Sheets

    Balance Sheets (Consolidated) (Unit: Million yen) Mar. Sep. Main Mar. Sep. Main 2020 2020 Increase/decrease 2020 2020 Increase/decrease Short-term Cash and borrowings deposit Current ＋8,720 ＋8,937 liabilities 10,434 20,755 Income taxes Current Accounts payable assets 28,342 37,504 receivable +504 (1

  8. Slide 8: Transition in Balance Sheets

    Transition in Balance Sheets (Consolidated) (Unit: Million yen) Assets Liabilities and net assets Investments and other assets Intangible assets Current liabilities Non-current liabilities Property, plant and equipment Current assets Total net assets Equity ratio 75.0% 70.3% 71.1% 66.9% 66.6% 54.8%

  9. Slide 9: Cash Flows

    Cash Flows (Consolidated) (Unit: Million yen) Six Months Six Months Operating Activities Ended Ended Year-on-year Investing Activities Sep. 30, 2019 Sep. 30, 2020 Ｂ-Ａ A B Financing Activities Income before Cash and Cash Equivalents at End of Period income taxes 1,098 1,381 283 Depreciation and amort

  10. Slide 10: Trend in Cash Flows

    Trend in Cash Flows (Consolidated) (Unit: Million yen) FY2016 FY2016 FY2017 FY2017 FY2018 FY2018 FY2019 FY2019 FY2020 1stH 2ndH 1stH 2ndH 1stH 2ndH 1stH 2ndH 1stH Operating Activities 1,909 1,909 742 742 1,830 1,830 1,303 1,303 2,372 2,372 1,533 1,533 2,949 2,949 1,978 1,978 4,232 4,232 Investing Ac

  11. Slide 11: Trend in Gross profit margin

    Trend in Gross profit margin (Unit: Million yen) Products sales License Revenue Gross profit margin (Products sales) Gross profit margin (including License Revenue) 73.7% 70.8% 72.3% 71.8% 69.9% 66.9% 66.8% 67.9% 65.1% 69.0% 67.1% 68.7% 67.5% 62.2% 67.9% 64.9% 65.1% 65.6% 1,048 2,506 1,002 10 512 55

  12. Slide 12: Trend in composition ratio of cost/expense

    Trend in composition ratio of cost/expense Operating Income R&D Expenses SG&A Cost of Sales 31.7％ 29.8％ 28.4％ 28.2％ 31.9％ 32.1％ 6,128 6,567 3,173 5,731 7,901 3,513 31.3％ 31.4％ 33.9％ 32.7％ 30.8％ 7,270 34.0％ Above number (％) 6,469 3,809 5,919 7,638 rate of sales 3,723 Lower number (Million yen) Amount

  13. Slide 13: Correlation between R&D expenses and main R&D pipeline

    Correlation between R&D expenses and main R&D pipeline (Unit: Million yen) R&D Expenses (before deducting) Apr. 1-Mar. 31 Apr. 1-Sep. 30 Preclinical 7,600 6,521 Clinical trial 4,865 5,270 4,551 3,539 Filed an applicaton 2,407 2,607 1,931 2,158 Approved FY2016 FY2017 FY2018 FY2019 FY2020(Forecast) JR

  14. Slide 14: FORWARD-LOOKING STATEMENT

    FORWARD- LOOKING STATEMENT This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All forward-looking statements regarding our plans, outlook, strategy and future performance are based on judgments derived

  15. Slide 15: Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.

    Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.

JCR Pharmaceuticals — H1 FY2020 Earnings Presentation on 6ix